Partnerships and Collaborations
Collaborations with John Theurer Cancer Center and Georgetown Lombardi Comprehensive Cancer Center
The Center for Discovery and Innovation, the John Theurer Cancer Center at the Hackensack University Medical Center, and the Georgetown Lombardi Comprehensive Cancer Center have combined forces to take on cancer. Together, the three institutions are developing and evaluating novel cancer treatments from their earliest conception in biomarker research and preclinical studies at CDI through early and late-phase clinical trials at the other institutions. As partners, we are also evaluating new technologies to accelerate research data exchange and enhance patient outcomes. Finally, we are developing and launching new studies that will provide a greater understanding of the ways in which cancer affects large populations. Learn more.
Hackensack University Medical Center (HUMC)
HUMC is a 900 bed, full-service hospital that was established in 1886 and has expanded tremendously in recent years. It has been named one of the nation’s top 50 hospitals, the top hospital in New Jersey, and one of the top 3 hospitals in the New York Metropolitan area. Research conducted at HUMC is supported by the David and Alice Jurist Institute for Research, which opened in 2000 to provide state of the art research facilities and services for both clinical and basic research, including an Institutional Review Board, Research Biosafety committee, Institutional Data Safety Monitoring Board, Office of Research Integrity, Sponsored Programs Office, Research Finance and Contracts Office, Research Compliance Office, Clinical trials Advisor, Research Biostatistician, and Office of Commercialization and Technology Ventures.
The John Theurer Cancer Center (JTCC)
Located at HUMC, the JTCC is the number-one ranked cancer center in New Jersey. It was listed among the top 50 cancer centers by U.S. News and World Report in 2013-2014, is the largest volume cancer-care provider in New Jersey, and one of the largest by volume in the United States. The JTCC is located across the street from the main HUMC campus. It has more than 300 ongoing clinical trials conducted independently and in partnership with government- and private-research centers and pharmaceutical companies, research consortiums, patient advocacy groups and the NIH.
Through recent investments in faculty recruitment and core equipment, the JTCC is fostering cancer research and related areas of biomedical research, including immunology and stem cell biology, at HUMC. As detailed below, five years ago the JTCC entered into a consortium agreement with the Lombardi Cancer Center at Georgetown University, thereby giving HUMC investigators access to the extensive core facilities at Lombardi. Learn more.
Georgetown Lombardi Comprehensive Cancer Center
Located at Georgetown University, the Lombardi Cancer Center is the only NCI-designated comprehensive cancer center in Washington, DC, and one of 41 in the country. Hackensack University Medical Center and the Lombardi Cancer Center have an executed Cancer Center Affiliation Agreement. Through this partnership, the Lombardi and JTCC consortium just successfully obtained NCI Comprehensive Care designation. The goal is to advance the science informing cancer and related disease diagnosis, treatment, and prevention by integrating their respective expertise in conducting clinical, translational, basic and population-based cancer research and training. Learn more.
New York Genome Center
HMH and the CDI joined the NYGC as institutional associate members. This partnership is intended to further our understanding of host genetics for oncology, neuropsychiatric behavioral disorders, and emerging infectious disease issues like COVID-19. In oncology, it seeks to use advanced genetic analyses to better understand risk factors for emergence of certain aggressive cancers, such as pediatric brain tumors; and why certain cancers fail to respond to immunotherapy. For behavioral disorders, it is focused on exploring the genetics underlying certain behavioral disorders and identifying genetic markers that help physicians predict and manage these disorders more effectively. Finally, in the period of COVID-19, CDI is working closely with the NYGC to better understand host and virus genomics that contribute to sever disease and poor clinical outcomes. The New York Genome Center, founded in 2011, serves as a multi-institutional collaborative hub focused on the advancement of genomic science and its application to drive novel biomedical discoveries. NYGC’s areas of focus include the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative disease, and neuropsychiatric disease. In 2020, the NYGC also has directed its expertise to COVID-19 genomics research.
Collaboration with Hackensack Meridian Health School of Medicine
The CDI strongly believes that medical education and scientific research go hand-in-hand. The CDI and the Hackensack Meridian Health School of Medicine share a campus, which lends itself to a close partnership between the two entities. Many of the faculty at the CDI will teach courses at the medical school, and the medical school faculty and students will become involved in the research projects taking place at the CDI. This will serve as an excellent platform for the sharing of ideas among different disciplines, an approach that is at the heart of CDI. Learn more.
Collaboration with Hackensack Meridian Health Hospitals
The CDI shares a network with 17 regional hospitals. This facilitates the sharing of resources, such as the biorepository, and promotes collaborations among the researchers at CDI with the many physicians within the network. It also enables clinicians to provide access to cutting-edge research to their patients. Learn more.